Code of Federal Regulations: Containing a Codification of Documents of General Applicability and Future Effect as of December 31, 1948, with Ancillaries and IndexDivision of the Federal Register, the National Archives, 1998 Special edition of the Federal Register, containing a codification of documents of general applicability and future effect ... with ancillaries. |
No grāmatas satura
6.10. rezultāts no 100.
27. lappuse
... oral dosing with tablets occurs 1- 3 hours after administration . The onset of therapeutic action of digoxin after oral tab- lets is 1-2 hours , with the peak therapeutic effect occurring 6-8 hours after dosing . INDICATIONS 1 ...
... oral dosing with tablets occurs 1- 3 hours after administration . The onset of therapeutic action of digoxin after oral tab- lets is 1-2 hours , with the peak therapeutic effect occurring 6-8 hours after dosing . INDICATIONS 1 ...
29. lappuse
... Oral digoxin is administered slowly or rap- idly as required until the desired therapeutic effect is obtained without symptoms of over- dosage . The amount can be predicted ap- proximately from the lean body mass of the patient with ...
... Oral digoxin is administered slowly or rap- idly as required until the desired therapeutic effect is obtained without symptoms of over- dosage . The amount can be predicted ap- proximately from the lean body mass of the patient with ...
30. lappuse
... orally in divided doses totaling 1-1.5 milliequivalents / kilogram ( 1 gram K contains 13.4 milliequivalents ) . When ... oral digitalizing dosages in chil- dren with normal renal function are : Newborn infants ( normal ) , up to 1 month ...
... orally in divided doses totaling 1-1.5 milliequivalents / kilogram ( 1 gram K contains 13.4 milliequivalents ) . When ... oral digitalizing dosages in chil- dren with normal renal function are : Newborn infants ( normal ) , up to 1 month ...
33. lappuse
... oral contraceptives . ( a ) Requirement for a patient package insert . The safe and effective use of oral contraceptive drug products requires that patients be fully informed of the benefits and the risks involved in their use . An oral ...
... oral contraceptives . ( a ) Requirement for a patient package insert . The safe and effective use of oral contraceptive drug products requires that patients be fully informed of the benefits and the risks involved in their use . An oral ...
34. lappuse
... oral contraceptive drug products that are subject to the re- quirements of this section are required to submit supplements under §314.70 ( c ) of this chapter to provide for the label- ing required by this section . Such la- beling may ...
... oral contraceptive drug products that are subject to the re- quirements of this section are required to submit supplements under §314.70 ( c ) of this chapter to provide for the label- ing required by this section . Such la- beling may ...
Saturs
279 | |
285 | |
290 | |
299 | |
310 | |
331 | |
339 | |
340 | |
223 | |
236 | |
238 | |
239 | |
240 | |
256 | |
257 | |
262 | |
263 | |
265 | |
270 | |
275 | |
351 | |
483 | |
588 | |
593 | |
696 | |
699 | |
761 | |
826 | |
865 | |
890 | |
911 | |
949 | |
Citi izdevumi - Skatīt visu
Bieži izmantoti vārdi un frāzes
abbre abbreviated application abbreviated new drug acid active ingredient adverse drug experience agency amended antibiotic application or abbreviated bacitracin bioavailability bioequivalence cation Center for Drug certification chapter clinical hold clinical investigation conducted control number copy Cosmetic Act digoxin dosage form dose Drug Administration drug application Drug Evaluation drug prod drug product Drug products containing drug substance Evaluation and Research Federal Food Food and Drug graph gredients hearing hydrochloride identified information requirements ap insulin intended inves investigational new drug labeling manufacturer marketing meet ment milligrams milliliters misbranded neomycin notice oral dosage orphan drug OTC drug product package paragraph percent person plication polymyxin proposed protocol recognized as safe reference listed drug request safe and effective safety section 502 Sodium sponsor statement submission Subpart sulfate tained tigational tion tive treatment treatment IND vestigational viated warning